News Quevos, a High-protein Snack Chip, Wins $15,000 at College New Venture Challenge The Polsky Center for Entrepreneurship and Innovation at the University of Chicago is pleased to announce the winners of the 2018 College New Venture Challenge (CNVC). The CNVC is the...
Technology New Platform For Targeted Immunomodulation And Vaccine Development There have been significant research efforts to develop effective vaccines that elicit a strong and durable T cell response against intracellular pathogens and cancer. A popular strategy has been to…
Technology Nanovaccine That Activates The NLRP3 Inflammasome & Enhances Tumor Specific Activation Of Anti-Cancer Immunity A major attention of vaccine adjuvant development has been focused on development of robust antibody-mediated protection against pathogens. However, such adjuvants have failed to elicit a robust T-cell mediated protection…
Technology Novel Nano-Formulation For Multi-TLR Agonists To Boost Immune Responses Against Solid Tumors Toll-like receptor (TLR) agonists are considered promising alternatives for the estimated 50 – 75% of all cancer patients who are non-responsive to checkpoint inhibitors, and immune activation is enhanced upon…
Technology Small Molecule Therapeutics For Inducing Trained Innate Immunity And Enhanced Anti-Tumor Responses Small molecule drugs developed to induce trained immunity in macrophage cells resulting in a heightened pro-inflammatory response without triggering a primary immune response The Unmet Need: Trained immunity induction that…
Technology Data-Driven Discovery Of Innate Immunomodulators Via Machine Learning-Guided High Throughput Screening Novel machine learning-enable platform to guide in vitro experimental screening and discovery of small molecule immunomodulators to improve immune responses The unmet need: Platform to resolve unregulated immune potentiator…
News 16 UChicago Researchers Awarded $7.2 Million from Chan Zuckerberg Biohub Chicago The Chan Zuckerberg Biohub Chicago has funded its first cohort of Investigators at its partner institutions – including 16 researchers from the University of Chicago. The funding – a total...
Technology Small Molecule Immunopotentiator Conjugates of NF-KB Activators as Adjuvants With Enhanced Efficacy And Reduced Toxicity Imidazoquinolinone derivatives that activate Toll-like receptor (TLR) 7/8 are small molecule immune potentiators (SMIPs) that have potent activity as vaccine adjuvants and as anti-tumor agents. However, these molecules have high…
Technology Tolerizing Agonist/Immunomodulator Loaded Liposomes for Long-Lived Immune Tolerance A failure of central immune tolerance typically driven by autoantigen specific T regulatory (Treg) cells is the primary cause of many autoimmune diseases. This technology generates antigen specific immune tolerance…
Technology Probing Cellular Activity Via Charge-Sensitive Quantum Nanoprobes Quantum nanoprobe system enables real-time probing of intracellular chemical environments and activity to advance biological and medical diagnostics The Unmet Need: Novel ways to probe cellular processes and improve biological…
News George Shultz Innovation Fund Awards $250K to Parasol Medtech and Signl The George Shultz Innovation Fund has selected two University of Chicago startups, Parasol Medtech and Signl, for an investment of $250,000 each. This year’s finals marked 15 years of the...
News Patent of the Week: Increased Safety and Improved Protection of Vaccines Researchers, including Aaron Esser-Kahn, an associate professor at UChicago’s Pritzker School of Molecular Engineering, have filed a patent application for a novel additive that limits undesirable vaccine-related side effects. Many...
